Ludimila Cavalcante, David P. Kelsen and Kenneth H. Yu Pages 6697 - 6701 ( 5 )
Due to its extremely high mortality rates, strong efforts continue to be made to develop new therapies in the treatment of pancreatic adenocarcinoma. The use of combined modality chemoradiotherapy for the treatment of pancreatic adenocarcinoma remains an approach with both promise and controversy. This article reviews the conflicting data with regards to role of combined modality therapy in pancreatic adenocarcinoma and provides an update on current studies in the field.
Pancreatic adenocarcinoma, chemoradiotherapy, review.
, , Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, 300 East 66th Street, New York, New York 10065, 646-888-4188.